Please login to the form below
Michael Cola resigns as president of Shire Specialty Pharmaceuticals
Leaves to "explore new career opportunities and challenges”
Shire's Michael Cola is to resign as president of the company's specialty pharmaceuticals business.
“With the company in a position of tremendous strength it is time for me to explore new career opportunities and challenges,” he said. “It has been an honour to work with my colleagues at Shire.”
Cola had been with Shire for seven years, joining as executive VP and general manager for the company's global therapeutic business units.
He assumed the role of president of the specialty pharmaceuticals business in 2006.
His role will be taken over by the company's CEO Angus Russell while the search for a new president is carried out.
Russell said: “As president of the SP business, Mike was instrumental in helping Shire transform itself from a company dominated by a single product in one market to a leading global biopharmaceutical company with a diversified product portfolio.”
Prior to joining Shire, Cola held several executive positions at pharma companies, including Merck, AstraZeneca and Safeguard Scientifics.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Senior External Communications Lead
-
£Competitive Salary
-
Account Director
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account Manager
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Sanofi doses first patient in global Kevzara COVID-19 trial
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- MHRA raises concerns over fraudulent coronavirus tests
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK
- Novartis donates malaria drug for COVID-19 clinical trials
- Making a difference with patient support
- Servier agrees to buy Symphogen to swell its cancer pipeline
- A Renewed Love of the NHS and National Recovery of the Patient-Doctor Relationship
- GSK and Vir Biotech join forces for COVID-19 antibodies
- Coronavirus causes Cancer Research UK to slash funding by £44m
- EMA backs compassionate use of Gilead’s remdesivir for COVID-19
PMHub
Virgo Health
Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...
Latest intelligence
- What challenges still face clinical trial recruitment and retention?
- Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
- “Fake News” and Credibility in Medical Publishing
- Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Quick links
Infographics
